QQ客服 官方微博 反馈留言

	Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
	Li, Xiaoying; Shao, Minhua; Wang, Shiming; Zhao, Xueying; Chen, Hongyan; Qian, Ji; Song, Xiao; Wang, Jiucun; Jin, Li; Wu, Junjie
刊名	TUMOR BIOLOGY
	2014
卷号	35期号:11
关键词	Clinical outcomes Methylenetetrahydrofolate reductase Non-small cell lung cancer Platinum-based chemotherapy Polymorphism
ISSN号	1010-4283
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4879356
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Li, Xiaoying,Shao, Minhua,Wang, Shiming,et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy[J]. TUMOR BIOLOGY,2014,35(11).
APA	Li, Xiaoying.,Shao, Minhua.,Wang, Shiming.,Zhao, Xueying.,Chen, Hongyan.,...&Lu, Daru.(2014).Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.TUMOR BIOLOGY,35(11).
MLA	Li, Xiaoying,et al."Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy".TUMOR BIOLOGY 35.11(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。